Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26768206 | 0.91 | ESR2 (0.83) | ESR2ESR1 | |
| SCHEMBL6828387 | 0.88 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL6919063 | 0.85 | ESR2 (0.73) | ESR2ESR1 | |
| SCHEMBL6828759 | 0.82 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL26780121 | 0.81 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL26768203 | 0.81 | ESR2 (0.79) | ESR2ESR1 | |
| SCHEMBL6923223 | 0.80 | ESR2 (0.65) | ESR2ESR1 | |
| SCHEMBL26768202 | 0.78 | ESR2 (0.84) | ESR2ESR1 | |
| SCHEMBL6924047 | 0.78 | ESR1 (1.00) | ESR2ESR1 | |
| SCHEMBL6919533 | 0.78 | ESR2 (0.79) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004073612-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO. INC. (US) | 2004-09-02 | — | — | WO | claimed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | ESR2 4060/4885ESR1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.